The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy

Since early 90  s platinum-based chemotherapy has been the mainstay of treatment for metastatic Non Small Cell Lung Cancer (NSCLC) (Non-small Cell Lung Cancer Collaborative Group, 1995; Schiller et al., 2002). However, during the last two decades front line treatment of metastatic NSCLC has profoundly changed mo ving from the old “one size fits all” concept to a “histology-based” approach and then, for a small subgroup of patients (i.e. EGFR mutated and ALK-rearranged NSCLCs), to a “molecularly-selected” one (Russo et al., 2015).

Source: Critical Reviews in Oncology Hematology - June 15, 2018 Category: Cancer & Oncology Authors: A Russo, T Franchina, GRR Ricciardi, G Toscano, S Schifano, G Lo Certo, A Battaglia, E Pant ò, M Scaffidi Fonti, V Adamo Source Type: research